Wei-Xiong Lim

Wei-Xiong Lim

Auto-generated profile, based on publicly available information

Wei-Xiong Lim

Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
CYChun-Yen Yu
Chun-Yen Yu
PHPo-Hsun Huang
Po-Hsun Huang
LTLeo Leung-Chit Tsang
Leo Leung-Chit Tsang
HHHsien-Wen Hsu
Hsien-Wen Hsu
WLWei-Xiong Lim
Wei-Xiong Lim
YCYu-Fan Cheng
Yu-Fan Cheng
Background: The purpose of this study was to assess the safety and efficacy of Yttrium-90 radioembolization using in unresectable hepatocellular carcinoma. Methods: From 2017 to 2021, 32 patients with unresectable hepatocellular carcinoma, with mean tumor diameter about 7cm (21 males, 11 females; median age, 57.5 years of age), treated with Yttrium-90 radioembolization using resin microspheres were reviewed at pre-Yttrium-90 and post-Yttrium-90 follow-up. Tumor response was assessed according to the modified Response Evaluation Criteria in Solid Tumors. Outcomes including overall survival and progression-free survival were reported. Results: Median follow-up was 18 months. At follow-up examinations at 3-, 6-, and 12-months follow-up, the overall survival rates were 94%, 87% and 59%, and the progression-free survival rates were 78%, 64% and 60%, respectively. Complete response, partial response, stable disease, and progressive disease were noted in 7 (21.9%), 14 (43.7%), 4 (12.5%), and 7 (21.9%) patients, respectively. The disease control rate was 78.1%, the objective response rate was 65.6%, and the successful downstage rate was 34.4% (11 of 32). Nine of thirty-two patients underwent resection or transplantation after Yttrium-90 radioembolization with 2-year overall survival being 100%. No serious adverse events occurred after Yttrium-90 treatment. Worse overall survival was related to the larger tumor, higher stage, Eastern Cooperative Oncology Group performance status, and Child-Pugh score. And worse progression-free survival was related to the higher tumor burden, and pre-Yttrium-90 serum α-fetoprotein level > 100. Conclusion: Yttrium-90 Radioembolization can control hepatocellular carcinoma well even in advanced diseases. Patients successfully downstaging/bridging to resection or transplantation have excellent overall survival.

1 September 2022 in Diagnostic and Interventional Radiology
Verified
Journal Article
Open access
CLChih Ying Lee
Chih Ying Lee
WLWei-Xiong Lim
Wei-Xiong Lim
CCChao-Long Chen
Chao-Long Chen
CYChee-Chien Yong
Chee-Chien Yong
CYChun-Yen Yu
Chun-Yen Yu
HOHsin‐You Ou
Hsin‐You Ou
Intractable ascites (IA) is an uncommon but challenging complication after liver transplantation. Splenic artery embolization (SAE) modulates the splenic artery and regulates portal flow. This study aimed to evaluate the efficacy and safety of SAE using the Amplatzer vascular plug (AVP) versus coil embolization for post-living-donor liver transplantation (LDLT) IA. This retrospective study evaluated consecutive patients from 1 center who received LDLT (n = 1410) between March 2006 and August 2019. The inclusion criteria for SAE were splenomegaly with IA after LDLT. Totally 15 patients underwent SAE for post-LDLT IA. Eleven patients who received AVP embolization (age, 51.2 ± 15.1 years; range, 8-63 years; 5 men and 6 women) were compared with 4 patients receiving coil embolization (age, 30.8 ± 30.8 years; range, 1.5-63 years; 2 men and 2 women). AVP and coil embolization both significantly reduced portal vein hyperflow (plug/coil; P < .001/.006) and decreased ascites volume (plug/coil; P < .003/.042). The benefits of AVP embolization included shorter procedure time (P = .029), significantly reduced splenic volume (P = .012), increased liver volume (P = .012), decreased spleen/liver ratio (P = .012), and improvement of pancytopenia (P = .008) due to secondary hypersplenism. No significant differences were found between the two groups in the length of hospital stay or complications such as splenic infarction, pancreatitis, or sepsis. SAE using AVP and coil embolization provide effective and safe methods for managing patients with IA after LDLT. AVP embolization may be more efficient than coil embolization, providing more effective reduction of ascites volume and the advantages of shortened procedure time and improvement of hypersplenism.

1 January 2024 in Diagnostic and Interventional Radiology
Verified
Journal Article
Open access
SLSieh-Yang Lee
Sieh-Yang Lee
WLWei-Xiong Lim
Wei-Xiong Lim
KWKuan-Ting Wu
Kuan-Ting Wu
CWCheng-Ta Wu
Cheng-Ta Wu
CHChung-Cheng Huang
Chung-Cheng Huang
CCChingDi Chang
ChingDi Chang
PURPOSE The present study aims to assess the short-term clinical outcomes and safety of transarterial embolization (TAE) for symptomatic hand osteoarthritis (OA) refractory to conservative treatment. METHODS The present retrospective cohort pilot study included nine patients who underwent TAE for symptomatic OA -associated hand pain in a single tertiary center between November 2022 and January 2023. The baseline and post -procedural OA -associated hand pain and function were assessed using the visual analog scale (VAS) and the Australian Canadian Hand Osteoarthritis Index (AUSCAN). The use of conservative treatment and pain medications was also recorded. Post -procedural adverse events were evaluated according to the Society of Interventional Radiology classification. RESULTS Compared with the baseline, the overall VAS scores were significantly decreased at 1 -week, 1 -month, 3 -months, and 6 -months after TAE (76 +/- 15 mm versus 34 +/- 18 mm, P < 0.001; 32 +/- 11 mm, P < 0.001; 21 +/- 15 mm, P < 0.001; 18 +/- 19 mm, P = 0.002). Similarly, improvement in the mean total AUSCAN scores (22.0 +/- 10.0 versus 13.2 +/- 6.6, P = 0.007; 14.11 +/- 7.3, P = 0.004; 9.8 +/- 6.8, P = 0.004; 9.3 +/- 7.4, P = 0.011) were documented. The use of other conservative treatment methods also gradually decreased. There were no severe adverse events reported during the follow-up period. CONCLUSION TAE is a feasible and safe treatment method for symptomatic hand OA refractory to conservative treatment. This minimally invasive procedure effectively relieves debilitating OA -associated joint pain and restores hand function with a durable treatment effect.

1 January 2026 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
PHPo-Hsun Huang
Po-Hsun Huang
HOHsin‐You Ou
Hsin‐You Ou
LTLeung-Chit Tsang
Leung-Chit Tsang
HHHsien-Wen Hsu
Hsien-Wen Hsu
WLWei-Xiong Lim
Wei-Xiong Lim
YCYu-Fan Cheng
Yu-Fan Cheng
Huang PH, et al. Korean J Radiol. 2026 Sep;27(9):890-896. https://doi.org/10.3348/kjr.2026.0364